39 results about "Aldosterone" patented technology

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

The invention provides an aldosterone antigen binding molecule and application thereof, and relates to the technical field of biology. The aldosterone antigen binding molecule is selected from a first antigen binding molecule containing CDR sequences as shown in SEQ ID NO.1 and SEQ ID NO.2 or a second antigen binding molecule containing CDR sequences as shown in SEQ ID NO.3 and SEQ ID NO.4. The aldosterone antigen binding molecule can bind an aldosterone antigen, and can be used for a method or a product for detecting aldosterone based on an immunological principle; the first antigen binding molecule and the second antigen binding molecule can also form an immune complex with a double-antibody sandwich structure with aldosterone, so that aldosterone is detected by a double-antibody sandwich principle.

Disclosed in the present invention are a pyrano-pyridine compound, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Provided in the present invention are a compound as shown in formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof. These compounds have a stronger inhibitory effect on aldosterone synthetase, but have almost no influence on cortisol synthetase, have high selectivity and higher safety, and can be used for preventing and / or treating various diseases related to aldosterone.

The invention discloses a metabolic marker aldosterone for screening heat stress Hu sheep as well as a screening method and application thereof, and belongs to the technical field of livestock serum markers. The metabolic marker for screening the heat stress Hu sheep is aldosterone; the screening method comprises the following steps: (1) taking blood of known heat-sensitive Hu sheep or heat-resistant Hu sheep as a standard test sample, taking blood of Hu sheep to be detected as a detection sample, and centrifuging to obtain a serum sample; (2) detecting the aldosterone concentration in the serum sample; and (3) calculating the aldosterone concentration average value of the standard test sample, taking the calculated aldosterone concentration critical value as a reference level, if the aldosterone concentration of the detection sample is higher than the reference level, determining that the detection sample is a heat-resistant Hu sheep, and if the aldosterone concentration of the detection sample is lower than the reference level, determining that the detection sample is a heat-sensitive Hu sheep. The aldosterone is used as the marker for detection, has the characteristics of high accuracy and high sensitivity, and can be directly used as an evaluation index for distinguishing the heat-sensitive Hu sheep from the heat-resistant Hu sheep.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The present disclosure relates to the use of angiotensin-converting enzyme and / or angiotensin-converting enzyme 2 as a fecal biomarker for the diagnosis of a disease or disorder related to the renin-angiotensin-aldosterone system, and also to the use of angiotensin-converting enzyme and angiotensin-converting enzyme 2 isoforms as fecal biomarkers for the detection of dysbiosis.

This application belongs to the field of immunoassay technology, and discloses an aldosterone sandwich antibody mAb5 or its antigen-binding fragment, its preparation method, and its applications. The aldosterone sandwich antibody mAb5 or its antigen-binding fragment includes a light chain variable region (VL) and a heavy chain variable region (VH). The light chain variable region (VL) includes complementarity-determining regions (LCDR1, LCDR2, and LCDR3), whose amino acid sequences are shown in SEQ ID NO. 1-3, respectively. The heavy chain variable region (VH) includes complementarity-determining regions (HCDR1, HCDR2, and HCDR3), whose amino acid sequences are shown in SEQ ID NO. 4-6, respectively. Using the aldosterone sandwich antibody mAb5 of this application to detect aldosterone standard antigens, the detection sensitivity is less than 7 pg / mL. Magnetochemiluminescence immunoassay of clinical samples shows good correlation with clinical results within the sample range of 0-1000 pg / mL, which is of great significance in the diagnosis and treatment of essential hypertension and other aldosterone-related diseases.

The application discloses a plant extraction compound for reducing blood pressure, a preparation method and application thereof. The compound is composed of high-purity silybin extract and a specific fusion polypeptide through molecular self-assembly. The sequence of the fusion polypeptide is shown in sequence SEQ ID NO:1, which innovatively integrates cell membrane penetration function, angiotensin II receptor 1 antagonism function and hydrophobic drug binding function. The core of the application is that through polypeptide-mediated active targeting, silybin is accurately delivered to the diseased blood vessel area, and the double synergistic mechanism of upstream ACE inhibition and downstream receptor blocking of the renin-angiotensin-aldosterone system is realized. In-vivo pharmacodynamic experiments prove that compared with single components, the compound can produce more significant and persistent antihypertensive effect, and can effectively reverse myocardial hypertrophy and fibrosis caused by hypertension, and show excellent synergistic therapeutic effect and target organ protection ability.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

Embodiments provide for methods of treatment for subjects suffering from a condition / disorder or disease for which the renin-angiotensin-aldosterone system (RAAS) plays at least some role. In one example, a method comprises administering to the subject an effective amount of one or more of an angiotensin receptor AT2R antagonist for a duration sufficient to elicit a desired response in the subject suffering from pancreatic cancer. The administering acts to reduce proliferation of tumor cells associated with the pancreatic cancer.

The application discloses a kind of medium chain inulin and its preparation method and application, belong to plant extraction technical field.The unique inulin structure and chain length disclosed in the application remodel intestinal microbiome and metabolome, especially selectively regulate key microorganisms such as coprococcus, bifidobacterium, parabacteroides, Clostridium_sensu_stricto_1 and Akkermansia, and metabolites such as nicotinamide, taurocholic acid, aldosterone, corticosterone, 2-(1H-indole-3-yl)acetic acid, 5-hydroxy-L-tryptophan, 5alpha-DHT and maltose, promote the improvement of host obesity and overall health status.The core microorganisms and metabolites identified by the technical scheme represent potential therapeutic targets for preventing or treating obesity and related metabolic symptoms.These findings support the development of inulin-based nutritional strategies to effectively manage weight by regulating specific microbiota and metabolome.

The application discloses a nucleic acid aptamer and derivatives, application and kit capable of specifically combining with aldosterone, and comprises a nucleotide sequence shown in SEQ ID No. 1, or a nucleotide sequence with high homology with the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with aldosterone, or a nucleotide sequence derived from the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with aldosterone. The application provides a nucleic acid aptamer and derivatives capable of combining with aldosterone, which have high specificity, stable chemical properties, are easy to preserve and label, and also correspondingly provides a screening method and application of the nucleic acid aptamer.

The invention provides application of aldosterone in diagnosis of amyotrophic lateral sclerosis, and particularly provides application of a reagent for detecting the aldosterone level in a sample in preparation of products for in-vitro diagnosis, auxiliary diagnosis and / or illness monitoring of amyotrophic lateral sclerosis. By simply detecting the aldosterone level in a serum sample, accurate diagnosis and illness monitoring of ALS can be realized.

The invention relates to the technical field of molecular biology, and provides a marker combination for diagnosing neonatal necrotizing enterocolitis and application thereof. The marker combination comprises a CC chemokine ligand 20, a heparin binding epidermal growth factor, angiotensin and aldosterone. Four markers related to neonatal necrotizing enterocolitis are obtained through research and screening, whether neonatal necrotizing enterocolitis occurs or not and the severity of neonatal necrotizing enterocolitis can be effectively judged based on the markers, and the markers have high sensitivity and specificity and can be used for detecting neonatal necrotizing enterocolitis. The kit can help clinical diagnosis and prognosis of neonatal necrotizing enterocolitis.

The invention relates to an application of urolithin A in preparation of a product for improving an endogenous estrogen level. The molecular formula of the urolithin A is C13H8O4, and the structural formula of the urolithin A is shown as a formula (I). The improvement of the endogenous estrogen level comprises the following steps: selectively regulating and controlling synthesis pathways of adrenal hormone and ovarian estrogen, and synergistically improving the in-vivo estrogen level. Besides, the urolithin A has good hormone regulation selectivity, can effectively inhibit cortisol secretion, and has no obvious influence on aldosterone level, so that blood pressure regulation and body fluid homeostasis are prevented from being interfered. The action characteristics lay a foundation for the application of the urolithin A in improvement of female climacteric hormone disorder and related health support directions, and the urolithin A has a wide prospect as an endogenous hormone regulation strategy. (I)

The invention discloses an anti-aldosterone antibody and application thereof, and relates to the field of antibodies. The anti-aldosterone antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for aldosterone detection, and has good affinity or activity.

The present invention belongs to the technical field of chemical pharmaceuticals. Provided in the present invention are an aldosterone synthetase inhibitor, and a preparation method therefor and the use thereof.

The invention discloses a protein pretreatment method, a renin angiotensin aldosterone system index detection method, a kit and application, and relates to the field of liquid chromatography-tandem mass spectrometry detection.The protein pretreatment method comprises the following steps that a biological sample containing renin angiotensin aldosterone system indexes is taken; mixing with an inhibitor solution, incubating, and adding a terminating agent to terminate the reaction to obtain an incubation solution; uniformly mixing the incubation solution with an internal standard solution and a protein precipitant, sequentially standing, centrifuging, and collecting supernate to obtain a sample to be detected. The protein precipitation pretreatment method provided by the invention can simplify the operation process, reduce the experiment cost, adapt to large-scale detection, efficiently remove impure proteins, weaken the matrix effect and improve the detection sensitivity and accuracy of a target object, and has a wide application prospect in the related field of RAAS system index detection.

The invention provides a deuterated 1, 2, 4-triazine compound or a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate, an enantiomer, a diastereoisomer and application of the deuterated 1, 2, 4-triazine compound or the pharmaceutically acceptable salt, prodrug, hydrate, solvate, enantiomer and diastereoisomer. The compound provided by the invention has the effect of inhibiting aldosterone synthetase, particularly can inhibit CYP11B2 with high selectivity, and also has excellent druggability, so that the compound can be used for treating diseases related to aldosterone synthetase.

The aim is to provide plasma biomarkers for bone infections in humans. [Solution] A plasma biomarker for bone infection comprising one or more substances selected from the group consisting of sphingosine-1-phosphate, taurocholic acid, glycololic acid, 11a,b hydroxyprogesterone, 15(S)-HETE-2, 13-dehydrochenodeoxycholic acid, 3,21-didihydroxy-5a-pregnane-20-one-2, aldosterone, bisacron-2, naringenin, tauro-α-mulicolic acid-6, 1-deoxysphingosine, 12(S)-HETE-2, 2-arachidonoylglycerol, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid, 3b-hydroxy-5-cholestic acid, AEA(22:4)-1, AEA(22:4)-2, bilbertin, sphingosine, malic acid, and succinic acid.

The invention discloses an essential oil pellet for resisting stress of cats as well as a preparation method and application of the essential oil pellet, and belongs to the technical field of veterinary traditional Chinese medicine preparations. The essential oil pellet is prepared from the following raw materials: extracts of wormwood, lavender and rhizoma acori graminei; the mass ratio of wormwood to lavender to rhizoma acori graminei is (1-2): (1-2): (1-2). The essential oil pellet prepared by the invention is filled into a nylon bag to prepare a sachet, and the sachet is suspended on the neck of a cat, added into a cat collar or put into cat clothes for use, so that the anti-stress capability of the cat can be remarkably improved, specifically, the feed intake of the cat is improved, and the weight of the cat is increased; meanwhile, the antioxidant index is improved, and the level of oxidative metabolite MDA in blood is reduced; in addition, the levels of cortisol and aldosterone as stress hormones and interleukin-6 as an inflammatory cytokine in cat serum can also be reduced.

The invention belongs to the technical field of chemical drugs and provides an aldosterone synthetase inhibitor as well as a preparation method and application thereof.

The invention relates to the technical field of drug carriers, in particular to a preparation method and application of self-assembled glycyrrhizic acid supported paeoniflorin nano-micelles. The preparation method adopts a membrane separation method and comprises the steps of solution preparation, membrane formation, hydration, particle size homogenization and purification. The prepared glycyrrhizic acid loaded paeoniflorin nano-micelle can be used for preparing medicines for treating liver cancer. According to the invention, the nano-micelle with the particle size in the range of 100-150nm can be stably prepared. The micelles can be efficiently taken by liver cells and are enriched in parenchymal liver cells in a targeted manner. Meanwhile, the targeted enrichment of the liver can reduce the kidney distribution of the medicine, so that the occurrence rate of pseudoaldosterone is reduced, and the renal toxicity of the medicine is reduced. According to the present invention, the cytotoxicity of the drug on normal liver cells is not increased while the inhibition effect on the liver cancer cell HepG2 can be significantly increased so as to provide the new strategy and the new treatment scheme for reducing the treatment dose, reducing the side effect or overcoming the drug resistance in the clinical application.

The invention belongs to the technical field of immunodetection, and discloses an aldosterone sandwich method antibody mAb7 or an antigen binding fragment thereof, and a preparation method and application thereof. The aldosterone sandwich method antibody mAb7 or the antigen binding fragment thereof comprises a light chain variable region VL and a heavy chain variable region VH, the light chain variable region VL comprises complementary determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequences of the light chain variable region VL and the heavy chain variable region VH are respectively shown as SEQ ID NO.1-3, the heavy chain variable region VH comprises complementary determining regions HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the heavy chain variable region VH are respectively shown as SEQ ID NO.4-6. When the aldosterone sandwich method antibody mAb7 is used for detecting aldosterone standard antigens, the detection sensitivity is lower than 10 pg / mL, a clinical sample is detected through a magnetochemiluminescence method, the correlation with R clinical comparison is good in the sample range of 0-1000 pg / mL, and the aldosterone sandwich method antibody mAb7 has important significance in the field of diagnosis and treatment of primary hypertension and other aldosterone abnormality related diseases.

This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.

This invention belongs to the field of bioassay technology, specifically relating to a cationic COF material and its application in the detection of angiotensin and aldosterone. Specifically, this invention successfully synthesizes a cationic covalent organic framework material with high specific surface area, abundant porous structure, and good thermal / chemical stability. Its surface quaternary ammonium salt cationic functional groups can selectively adsorb negatively charged angiotensin via electrostatic interactions and adsorb aldosterone via π-π conjugation and hydrophobic interactions. It exhibits excellent enrichment capacity and selectivity for four substances: Ang I, Ang II, Ang III, and Aldo, and can be recycled multiple times, effectively reducing the detection cost of large batches of clinical samples. By coupling the prepared SPE material with LC-MS / MS, a method for the simultaneous detection of Ang I, Ang II, Ang III, and Aldo in plasma was established, demonstrating good practical application value.

The invention discloses a lipid metabolism marker of palmitic acid induced islet tumor cells, application and a targeted pharmacological effect evaluation method, and belongs to the technical field of pharmacological effect evaluation. The lipid metabolism marker is at least one of corticosterone, phosphorylcholine, oleic acid, choline glycerophosphate, vitamin D3, gamma-linolenic acid, stearic acid, arachidonic acid, dehydroepiandrosterone, aldosterone, pregnanediol, sphingosine, sphingosine, eicosadienoic acid, alpha-linolenic acid, myristic acid, epinephrine, glutamic acid and (15Z)-tetracosenoic acid. The biomarker related to the drug effect is screened out and can be used for establishing a targeted pharmacological effect evaluation method to evaluate the direct influence of the drug on a specific target spot and the biological effect of the drug.

The invention belongs to the technical field of biological medicine, and relates to application of PARP1 as an MR co-regulatory factor in treatment of hypertension renal injury. The invention discovers that the expression of PARP1 in kidney tissues of a salt-sensitive hypertension renal injury rat model is up-regulated for the first time, and the expression of PARP1 in an aldosterone-induced human renal tubular epithelial cell injury model is also up-regulated; the PARP1 specific inhibitor PJ34 is adopted, so that the renal injury process of human renal tubular epithelial cells induced by aldosterone in vitro can be obviously reversed; in addition, PARP1 protein expression in in-vivo and in-vitro hypertensive renal injury models can be remarkably inhibited and the renal injury process can be effectively relieved by applying an MR antagonist fenerenone; the invention also discloses a functional interaction mechanism between the PARP1 and the MR, and the function can be completely blocked by the fenerenone. Therefore, the PARP1 can be used as a drug, a drug target or a target gene in gene therapy, is applied to prevention, alleviation and treatment of hypertension kidney injury, and can provide a new strategy for prevention and treatment of diseases.

The present invention belongs to the technical field of plant extraction. Disclosed are a medium-chain inulin, a preparation method therefor, and the use thereof. The unique inulin structure and chain length disclosed in the present invention reshape the gut microbiome and metabolome, and in particular, selectively modulate key microorganisms such as Faecalibacterium, Bifidobacterium, Parabacteroides, Clostridium_sensu_stricto_1 and Akkermansia, and metabolites such as nicotinamide, taurocholic acid, aldosterone, corticosterone, 2-(1H-indol-3-yl)acetic acid, 5-hydroxy-L-tryptophan, 5α-DHT and maltose, thereby promoting the amelioration of obesity and the improvement of the overall health of a host. The core microorganisms and metabolites identified by the technical solution represent potential therapeutic targets for preventing or treating obesity and related metabolic symptoms. These findings support the development of inulin-based nutritional strategies to effectively manage body weight by modulating specific microbiota and the metabolome.

The present disclosure provides compounds, compositions, and methods for modulating plasma membrane Cav1.3 calcium channels and treating diseases or disorders (e.g., Parkinson's disease, aldosteronism) with the compounds or compositions thereof. In particular, disclosed herein are modified pyrimidine-2,4,6-triones and modified dihydropyridines that have elevated potency and selectivity for Cav1.3 Ca2+ channels, and compositions and formulations thereof.